COMMUNIQUÉS West-GlobeNewswire

PotNetwork Holding Inc. Exceeds 1 Million in Sales for First 15 Days of February

27/02/2018 - 12:00

FT LAUDERDALE, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- via OTC PR WIRE-- PotNetwork Holding, Inc. (OTC Pink:POTN ) (“Company”) announced today that its wholly owned subsidiary, Diamond CBD, Inc., has reported that the [...]

Integra LifeSciences Reports Fourth Quarter and Full-Year 2017 Financial Results

27/02/2018 - 12:00

PLAINSBORO, N.J., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART ) today reported financial results for the fourth quarter and full-year ended December 31, 2017. Highlights: [...]

Green Cures & Botanical Distribution, Inc. Partners with Humboldt Cannabis AF to Produce Licensed Cannabis and CBD Products

27/02/2018 - 11:30

LOS ANGELES, CA , Feb. 27, 2018 (GLOBE NEWSWIRE) -- Green Cures and Botanical Distribution, Inc. (OTC PINK: GRCU), an innovative hemp-infused nutrition, botanical, sports, and body care products company, has signed a [...]

Amarin Reports Record Fourth Quarter and Full Year 2017 Financial Results and Provides Update on Operations

27/02/2018 - 11:00

Record Revenue of $181.1 Million and $ 53.9 Million for Full Year and Fourth Quarter 2017 REDUCE-IT Cardiovascular Outcomes Study Remains on Schedule to Report Top-Line Results Before the End of Q3 2018 Management to [...]

Verona Pharma plc ("Verona Pharma" or the "Company") Reports Operational Update and Financial Results for Full Year Ended December 31, 2017

27/02/2018 - 08:00

LONDON, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq: VRNA ) (Verona Pharma), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for [...]

OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment

27/02/2018 - 07:30

NANTES, France, Feb. 27, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN:FR0012127173) (Mnémo:OSE), today announces that the first approvals to resume patient accrual in the global Tedopi ® Phase 3 trial have been [...]

Photocure ASA: Results for the fourth quarter of 2017

27/02/2018 - 07:16

Oslo, Norway, 27 February 2018: Photocure ASA (OSE: PHO ), today reported a revenue growth of 27% for the important U.S. market in the fourth quarter of 2017, contributing to Hexvix ® /Cysview ® revenues of NOK 39.4 [...]

Basilea reports significantly improved financial results in 2017

27/02/2018 - 07:16

54% increase in total revenue, amounting to CHF 101.5 million Operating loss reduced by 68% to CHF 14.1 million Cash position as of year-end 2017 increased to CHF 310.7 million License and distribution agreements in [...]

Vistin Pharma ASA : Fourth quarter 2017 results

27/02/2018 - 07:01

Oslo, Norway, 27 February 2018 Vistin Pharma had a revenue of NOK 41.6 million in the fourth quarter 2017, compared to NOK 32.5 million in the fourth quarter 2016. Adjusted EBITDA from continuing operations came to [...]

Targovax to present at Biologics World Nordic 2018

27/02/2018 - 07:01

Oslo, Norway, 27 February 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, announces that the Company will present at the following [...]

Biocartis Group NV: Disclosure of a transparency notification

27/02/2018 - 07:01

PRESS RELEASE : REGULATED INFORMATION 27 February 2018, 07:00 CET Disclosure of a transparency notification (Article 14, paragraph 1 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings) Mechelen, [...]

Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders

27/02/2018 - 05:30

SAN DIEGO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT ), a leading RNA medicines company, today announced that, based on the preliminary vote count provided by its transfer agent [...]

BioStem Technologies Inc. Announces Intent to Acquire GIINT

27/02/2018 - 02:27

Pompano Beach, FL, Feb. 26, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in [...]

Kane Biotech Sues Nestlé

27/02/2018 - 02:05

WINNIPEG, Manitoba, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE ) (OTCQB:KNBIF), (the “Corporation” or “Kane Biotech”) today announced that it has filed a lawsuit against Nestec, Ltd., a/k/a Nestec, [...]

Akorn Issues Statement on Investigation

27/02/2018 - 01:47

LAKE FOREST, Ill., Feb. 26, 2018 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX ), a leading specialty generic pharmaceutical company, today issued the following statement: “Akorn and Fresenius Kabi AG, with the [...]

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

26/02/2018 - 23:06

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients Positive preliminary results support Viaskin Milk's potential as the first treatment for patients suffering from IgE- [...]

DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait

26/02/2018 - 23:06

DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait Les résultats préliminaires sont positifs et Viaskin Milk pourrait être le premier traitement potentiel [...]

DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

26/02/2018 - 23:01

Press Release Montrouge, France, February 26, 2018 DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients Positive preliminary results support Viaskin Milk's potential as the [...]

DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait

26/02/2018 - 23:01

Communiqué de presse Montrouge, France, le 26 février 2018 (22h30 CET) DBV Technologies annonce les résultats de l'étude de Phase II de Viaskin Milk chez les patients allergiques au lait Les résultats préliminaires sont [...]